Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shaky Q1 For Lupin But Upbeat On FDA Generics Reform, Biosimilars

Executive Summary

Lupin reported a weak first quarter, but the management sees "tremendous upside" in opportunities arising from the US FDA’s recent initiatives to encourage generic competition. A build-up also appears on the cards for biosimilars, where the company now has a “financing partner” for a project.

You may also be interested in...

Amazon Offers Hope As US Pricing Approaches ‘Pain Point’ For Manufacturers, Says Lupin

Pricing pressure in the US continued to hurt Lupin, denting its Q2 earnings, with the company’s management suggesting that manufacturers, both US and Indian, could be nearing their “pain point”. CEO Vinita Gupta also maintained that a potential entry of Amazon into the pharmacy business could be “real positive” for the generic industry.

Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House

The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.

Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development

US agency’s list of off-patent, off-exclusivity drugs that lack generic versions is aimed at improving transparency and encouraging competition, but almost half the 267 listed products involve complex issues that would require further decision-making by FDA ahead of ANDA submission.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts